[account_shop_links]
Informing the pharmaceutical drug development, manufacturing and commercialization industry.
Cary, NC – July 25, 2017 – Industry Standard Research’s (ISR’s) Development vs Commercial Outsourced Manufacturing Practices: Biologics report offers insight into how respondents in different outsourcing scenarios prioritize different CMO selection attributes. Whether selecting a CMO for the first time or for the 50th time, this information is particularly of value for drug innovators who are entering into a different outsourcing scenario, needing to increase the number of suppliers they are using, or wanting to change contract manufacturers or their outsourcing approach for any reason.
“Right-first-time measurements landed a top 3 position among development-stage drug product respondents,” explained Kate Hammeke, Vice President, market research at ISR, “but this qualification did not penetrate the top 10 attribute list among respondents outsourcing development or commercial API manufacturing or commercial-scale drug product manufacturing. This is one simple reminder of how different outsourcing situations, influenced by outsourcing experience, internal expertise, and available capacity influence CMO selection priorities. This type of information is invaluable to CMOs in developing their sales and marketing strategies because it helps them know precisely which of their strengths to mention to each of their target audiences.”
The report highlights key differences in outsourcing preferences and behaviors among respondents who fall into four different categories of outsourcers of biologic manufacturing: development-stage API, commercial-scale API, development-stage drug product, and commercial-scale drug product. Drug innovators will gain insight into these four different outsourcing scenarios, enabling them to make more educated purchases of CMO services based on their unique needs and to gain outsourcing advantages by following the advice and experiences of their industry peers. Contract manufacturers will gain a better understanding of customers’ requirements and how they change as a compound moves through the development to commercialization process.
Key statistics from the report, broken out and analyzed by the aforementioned outsourcing scenarios, include: outsourcing drivers, use of preferred providers, outsourcing models, CMO familiarity and use, perceived leadership, proposal volume, and CMO preference. In addition, ISR analyzes which attributes are influencing CMO selection and which CMO attributes are gaining in importance.
For more information on ISR’s “Development vs Commercial Outsourced Manufacturing Practices: Biologics” report, please visit ISR’s report page.
About Industry Standard Research
Industry Standard Research is the premier, full service market research provider to the pharma and pharma services industries. With over a decade of experience, ISR delivers an unmatched level of domain expertise. For more information about ISR’s off-the-shelf intelligence and custom research offerings, please visit the company’s website at www.isrreports.com, email info@isrreports.com or follow ISR on Twitter @ISRreports.
